Search - tctmd.com

Displaying 81 - 93 of 93

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Daily News

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Todd Neale

March 06, 2017

News Daily News

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Yael L. Maxwell

October 28, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Shelley Wood

May 25, 2016

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Betrixaban Approved for Prevention of VTE

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

FDA Approves Next-Gen CoreValve Evolut PRO Valve

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content